Clinical trial · Observational
T2* MRI Analysis for Sarcoma
An Exploratory, Pilot Study Evaluating T2* Imaging for Adult Sarcoma
NCT03658343CI-TRIAL-00086323completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
T2\* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Magnetic Resonance Imaging | — | UNRESOLVED | — |
| Radiotherapy | — | UNRESOLVED | — |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| T2* Imaging | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- T2* Imaging
- description
- Participants undergo T2\* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
- interventionNames
- Diagnostic Test: T2* Imaging
Primary outcomes (1)
- measure
- Change in ferric iron levels detected by T2* MRI
- timeFrame
- baseline and 8 weeks
- description
- Change from baseline in Fe3+ iron levels
Secondary outcomes (1)
- measure
- Change in ferrous iron levels detected by T2* MRI
- timeFrame
- Baseline and 8 weeks
- description
- Change from baseline in Fe2+ iron levels
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * pathologically confirmed Sarcoma, by biopsy or excision * prescribed radiation therapy as per standard of care * treatment to begin within 5 weeks after surgery or biopsy * ECOG 0, 1, or 2 * ability and willingness to provide informed consent Exclusion Criteria: * \< 18 years of age
References
Publications (0)
Data not yet available
No reference posted for this study.